Federal regulators on Wednesday approved Eli Lilly’s new weight-loss pill, a second daily oral medication to treat obesity and other weight-related conditions.
VASCADE MVP XL is now approved for larger sheaths used in market-leading PFA and LAAC technologies
Serenity Medical announced today that it received FDA Humanitarian Device Exemption (HDE) approval for its novel River stent.
MicroPort announced that it received FDA breakthrough device designation for its Apollo Dream sirolimus target-eluting stent system.
HENDERSON, Nev., March 31, 2026 /PRNewswire/ — Restore Robotics today announced it has received additional 510(k) clearances from the U.S. Food and Drug Administration (FDA) for the remanufacturing of two more da Vinci Xi® robotic surgical instruments. This milestone expands Restore Robotics’ growing portfolio of cleared instruments and further strengthens its position as a leader in robotic instrument remanufacturing.
IDE approval by the FDA expands global trial to the United States as first study participant is treated in the United Kingdom
Garmin users can now integrate with the temperature-powered Natural Cycles app, which turns Garmin skin temperature data into fertility insights for women’s health
NEWTOWN, Conn., March 31, 2026 /PRNewswire/ — Elidah today announced FDA clearance of Elitone for Men, a non-invasive, at-home treatment designed to help men regain bladder control after prostate surgery, addressing a significant and often overlooked men’s health condition. Urinary incontinence, or bladder leakage, is one of the most common and disruptive complications following prostate procedures, yet men have had few options to actively support recovery at home.
DURHAM, N.C., March 31, 2026 /PRNewswire/ — Baebies announced FDA 510(k) clearance and CLIA-waiver approval for the FINDER® Flu A&B/SARS-CoV-2 Test, an ultra-rapid RT-PCR assay on the FINDER platform. This establishes FINDER as the first molecular point-of-care platform with multifunctional capabilities. The compact, automated system delivers PCR-quality results during the patient visit, with positives as early as 15 minutes and negatives in about 20 minutes, giving urgent care centers, emergency departments, clinics, and other decentralized settings the speed, ease of use, and reliability needed for better diagnostic decisions.
Medtronic (NYSE:MDT) today announced CE mark approval and the first commercial European implants for its OmniaSecure system.